(Q57911942)

https://api.crossref.org/works/10.1039%2FC4SC00685B

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Antibody-drug conjugates for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

A Small-Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Engineering folate-drug conjugates to target cancer: from chemistry to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Preclinical antitumor activity of a novel folate-targeted dual drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

A human protein atlas for normal and cancer tissues based on antibody proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Intracellular and extracellular carbonic anhydrases cooperate non-enzymatically to enhance activity of monocarboxylate transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

4-Functionalized 1,3-diarylpyrazoles bearing benzenesulfonamide moiety as selective potent inhibitors of the tumor associated carbonic anhydrase isoforms IX and XII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Antibody-drug conjugate payloads

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Synthesis and evaluation of near-infrared fluorescent sulfonamide derivatives for imaging of hypoxia-induced carbonic anhydrase IX expression in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B

Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4SC00685B